Sign In
Buy RGEN
$149.78
+2.72 (+1.85%)
At Close: Aug 04, 2026
Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
04:42pm, Wednesday, 18'th Mar 2026
Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Cinctive Capital Management LP Takes Position in Repligen Corporation $RGEN
04:31am, Monday, 16'th Mar 2026
Cinctive Capital Management LP bought a new stake in shares of Repligen Corporation (NASDAQ: RGEN) during the undefined quarter, according to its most recent filing with the SEC. The firm bought 25,42
Repligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Brokerages
02:51am, Friday, 13'th Mar 2026
Shares of Repligen Corporation (NASDAQ: RGEN - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen brokerages that are presently covering the firm, Marketbeat reports. O
Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript
02:20pm, Tuesday, 10'th Mar 2026
Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y
10:11am, Wednesday, 25'th Feb 2026
RGEN tops Q4 EPS estimates as revenues jump 18% Y/Y, with solid organic growth and stronger margins heading into 2026.
Repligen Corporation (RGEN) Q4 2025 Earnings Call Transcript
02:28pm, Tuesday, 24'th Feb 2026
Repligen Corporation (RGEN) Q4 2025 Earnings Call Transcript
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
10:40am, Tuesday, 24'th Feb 2026
Repligen (RGEN) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.44 per share a year ago.
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
07:30am, Tuesday, 24'th Feb 2026
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f
Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells
06:08pm, Sunday, 15'th Feb 2026
In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profit
Repligen (RGEN) to Release Quarterly Earnings on Thursday
04:30am, Thursday, 12'th Feb 2026
Repligen (NASDAQ: RGEN - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of $0.44 per
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
07:30am, Tuesday, 10'th Feb 2026
Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET
Bessemer Group Inc. Sells 238,450 Shares of Repligen Corporation $RGEN
04:52am, Monday, 09'th Feb 2026
Bessemer Group Inc. trimmed its stake in Repligen Corporation (NASDAQ: RGEN) by 95.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Comm
Conestoga Mid Cap Composite Q4 2025 Leaders And Laggards
10:09am, Sunday, 25'th Jan 2026
Conestoga Mid Cap Composite Q4 2025 Leaders And Laggards
Repligen Corporation (RGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:55am, Wednesday, 14'th Jan 2026
Repligen Corporation (RGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
07:30am, Tuesday, 06'th Jan 2026
WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected
